PMID- 27000731
OWN - NLM
STAT- MEDLINE
DCOM- 20160912
LR  - 20201226
IS  - 1532-8686 (Electronic)
IS  - 0037-1963 (Linking)
VI  - 53
IP  - 2
DP  - 2016 Apr
TI  - Haploidentical stem cell transplantation: anti-thymocyte globulin-based 
      experience.
PG  - 82-9
LID - S0037-1963(16)00005-6 [pii]
LID - 10.1053/j.seminhematol.2016.01.004 [doi]
AB  - Haploidentical stem cell transplantation (haplo-SCT) with an anti-thymocyte 
      globulin (ATG) preparative regimen is associated with induced immune tolerance, 
      rapid hematopoietic recovery, effective prevention of graft-versus-host disease 
      (GVHD), and lower non-relapse mortality (NRM). This has become a common and 
      successfully applied protocol in patients with hematological diseases undergoing 
      haplo-SCT. Survival rates among patients who undergo unmanipulated haploidentical 
      blood and marrow transplantation (HBMT) with anti-thymocyte globulin (ATG)-based 
      regimens are comparable to those following human leukocyte antigen (HLA)-matched 
      sibling transplantation or unrelated donor transplantation. Unmanipulated HBMT 
      can also be successfully used as a post-remission treatment algorithm for acute 
      lymphoblastic leukemia (ALL) and adult acute myeloid leukemia (AML) in cases with 
      unfavorable cytogenetics. Future investigations should focus on further improving 
      donor selection, optimizing allografts, dealing with primary graft failure, and 
      relapse prophylaxis and treatment.
CI  - Copyright (c) 2016 Elsevier Inc. All rights reserved.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AD  - Peking University People׳s Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 
      100044, China.
FAU - Huang, Xiao-Jun
AU  - Huang XJ
AD  - Peking University People׳s Hospital, Peking University Institute of Hematology, 
      Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing 
      100044, China; Peking-Tsinghua Center for Life Sciences, Beijing 100871, China. 
      Electronic address: xjhrm@medmail.com.cn.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20160118
PL  - United States
TA  - Semin Hematol
JT  - Seminars in hematology
JID - 0404514
RN  - 0 (Antilymphocyte Serum)
SB  - IM
MH  - Antilymphocyte Serum/*therapeutic use
MH  - Haploidy
MH  - Hematologic Diseases/therapy
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Stem Cell Transplantation
MH  - Transplantation, Homologous
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Anti-thymocyte globulin
OT  - Haploidentical stem cell transplantation
OT  - Hematological malignancies
OT  - Myeloablative conditioning
OT  - Reduced-intensity conditioning
EDAT- 2016/03/24 06:00
MHDA- 2016/09/13 06:00
CRDT- 2016/03/23 06:00
PHST- 2016/03/23 06:00 [entrez]
PHST- 2016/03/24 06:00 [pubmed]
PHST- 2016/09/13 06:00 [medline]
AID - S0037-1963(16)00005-6 [pii]
AID - 10.1053/j.seminhematol.2016.01.004 [doi]
PST - ppublish
SO  - Semin Hematol. 2016 Apr;53(2):82-9. doi: 10.1053/j.seminhematol.2016.01.004. Epub 
      2016 Jan 18.